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PDCD4 controls the G1/S-phase 
transition in a telomerase-
immortalized epithelial cell line 
and affects the expression level and 
translation of multiple mRNAs
Astrid Haas1, Benedikt S. nilges2, Sebastian A. Leidel  2,3 & Karl-Heinz Klempnauer1*
PDCD4, the protein encoded by the tumor suppressor gene PDCD4 (programmed cell death 4) has been 
implicated in the control of cellular transcription and translation by modulating the activity of specific 
transcription factors and suppressing the translation of mRNAs with structured 5′-UTRs. Most studies of 
human PDCD4 have employed tumor cell lines, possibly resulting in a biased picture of its role in normal 
cells. Here, we have studied the function of PDCD4 in a telomerase-immortalized human epithelial cell 
line. We show for the first time that PDCD4 is required for the G1/S-transition, demonstrating its crucial 
role in the cell cycle. Inhibition of p53-dependent activation of p21WAF1/CIP1 overrides the requirement 
for PDCD4 for the G1/S-transition, suggesting that PDCD4 counteracts basal p53 activity to prevent 
activation of the G1/S checkpoint by p53. Transcriptome and ribosome profiling data show that silencing 
of PDCD4 changes the expression levels and translation of many mRNAs, providing an unbiased view of 
the cellular processes that are affected by PDCD4 in an epithelial cell line. Our data identify PDCD4 as a 
key regulator of cell cycle- and DNA-related functions that are inhibited when it is silenced, suggesting 
that decreased expression of PDCD4 might contribute to tumor development by compromising 
genomic integrity.
The PDCD4 (Programmed cell death 4) gene encodes a highly conserved nuclear-cytoplasmic shuttling protein 
that acts as a tumor suppressor (for recent reviews see refs. 1,2). PDCD4 contains two highly structured MA-3 
domains located in the central and C-terminal parts of the protein, which mediate protein-protein-interactions 
with the translation initiation factor eIF4A. A putative unstructured domain at its N-terminal has been shown 
to mediate protein-protein- and protein-RNA-interactions3–10. PDCD4 was initially shown to suppress tumor 
development in an in-vitro mouse keratinocyte model of tumor promotion11, but has since been implicated as a 
tumor suppressor in a broad spectrum of human tumors12–19. Down-regulation of PDCD4 expression in tumor 
cells occurs by different mechanisms. PDCD4 mRNA is targeted by several microRNAs, most prominently onco-
genic microRNA miR-21, whose over-expression in cancer cells down-regulates PDCD4 expression20,21. On the 
protein level, p70(S6K) kinase-mediated phosphorylation of PDCD4 triggers its ubiquitination by the E3 ubiq-
uitin ligase complex SCF(βTRCP) and its subsequent degradation22. A large body of work has suggested that 
down-regulation of PDCD4 expression contributes to tumor development by stimulating the mobility and the 
metastatic potential of tumor cells18–20,23–25. Furthermore, silencing of PDCD4 has been shown to affect the cel-
lular DNA-damage response, suggesting that decreased PDCD4 expression might compromise genomic stability 
and contribute to tumor development26,27.
PDCD4 has emerged as a critical regulator of protein translation due to its ability to interact with and inhibit 
the function of the eukaryotic translation-initiation factor eIF4A, a RNA helicase that promotes the unwinding 
of mRNA secondary structures present in the 5′-untranslated regions (UTRs) of certain mRNAs3,4,19,28. PDCD4 
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is therefore thought to suppress the cap-dependent translation of mRNAs with 5′-structured UTRs. This was 
supported by studies showing that PDCD4 suppresses the translation of RNAs containing engineered 5′-hairpin 
structures3,4 as well as by the identification of specific mRNAs regulated by this mechanism19,28. However, alterna-
tive mechanisms of translational suppression involving direct RNA-binding of PDCD4 to the coding regions of 
specific mRNAs have also been described29,30.
Our current understanding of the function of human PDCD4 derives mostly from work carried out with 
transformed tumor cells. Here, we have used a telomerase-immortalized human epithelial cell line to study the 
effect of PDCD4 silencing on the cell cycle, gene expression and mRNA translation. Our work reveals a novel 
role of PDCD4 in the regulation of the cell cycle and provides a more complete picture of its cellular functions.
Results
PDCD4 is required for the G1/S-transition in RPE cells. Our current understanding of PDCD4′s role 
in human cells is largely based on studies using transformed tumor cell lines. Such studies have provided insight 
into the function of PDCD4 as a tumor suppressor but may not reveal an unbiased picture of its cellular roles 
due to the aberrant nature of these cells. To study the function of human PDCD4 in normal cells we have used 
the telomerase-immortalized hTERT-RPE-1 cell line (referred to as RPE hereafter) as a model of untransformed 
epithelial cells. Expression of PDCD4 was effectively silenced by two different siRNAs (Fig. 1a). The cells did not 
show obvious changes of their spindle-shaped fibroblast-like morphology when viewed under the microscope. To 
explore whether PDCD4 knockdown disrupts the cell cycle we examined the cell cycle distribution of asynchro-
nous cultures of RPE cells treated with PDCD4-specific or control siRNAs by flow cytometry. The cell cycle pro-
files of the control and PDCD4 knock-down cells were different. Specifically, the abundance of S- and G2-phase 
cells was strongly decreased in cultures treated with the two different PDCD4-specific siRNAs compared to the 
control cells (Fig. 1b and Supplementary Table S1). Both siRNAs yielded similar results suggesting that the partial 
G1 arrest is induced by PDCD4 knockdown and not by off-target effects.
Based on this observation we hypothesized that PDCD4 knockdown decreases the proliferation rate of the 
cells. To test whether this is the case, we monitored the growth of the cells over a period of 5 days following knock-
down with PDCD4-specific or control siRNA. We used a qualitative assay of cell proliferation by plating equal 
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Figure 1. PDCD4 knockdown affects the cell cycle and growth properties of RPE cells. (a) Silencing of PDCD4 
expression in RPE cells with PDCD4-specific siRNA-1 and -2. (b) Cell cycle distribution of RPE cells treated 
with control or PDCD4-specific siRNA-1 and -2. G1 and G2/M peaks are marked. (c) Equal numbers of RPE 
cells treated with control siRNA or PDCD4 siRNA-1 or -2 were plated onto replicate tissue culture plates. The 
growth of the cells was followed over several days by fixing one of the replicate plates at each indicated day of 
culture with formaldehyde. After 5 days of culture all plates were stained simultaneously with crystal violet. 
(d) RPE cells treated with siRNAs as in A. The cells were then incubated in medium supplemented with 10 
μCi/ml 3H-thymidine for 1 hour. Subsequently, the radioactivity incorporated into DNA was determined by 
TCA-precipitation and liquid scintillation counting. The bars indicate the percentage of DNA synthesis (with 
standard deviation) of the PDCD4 siRNA treated cells relative to control cells. Asterisks indicate statistical 
significance (**p < 0.01; ***p < 0.001; students-t test). (e) RPE cells were treated for 24 h with control siRNA or 
PDCD4-specific siRNA-1 and -2. The cells were then arrested in the late G1 phase by incubation for 24 hours in 
the presence of 0.5 mM mimosine. Cells were then processed immediately for flow cytometry analysis or were 
washed with fresh medium lacking mimosine and cultivated for additional 10 or 20 hours before being analyzed 
by flow cytometry. G1 and G2/M peaks are marked.
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numbers of cells on replicate culture plates and visualized their proliferation by crystal violet staining (Fig. 1c). 
We found that the intensity of staining of cells transfected with PDCD4-specific siRNAs was decreased compared 
to the control cells, suggesting decreased proliferation upon Pdcd4 knockdown. As in the previous experiment, 
both Pdcd4-specific siRNAs had similar effects.
To substantiate the finding that PDCD4 knockdown reduces the proliferation of RPE cells we quantified their 
DNA-synthesis activity as an independent measure of proliferation. We performed 3H-thymidine incorporation 
assays by incubating equal numbers of control- and PDCD4-knockdown cells for 1–2 hours in the presence of 
radiolabeled thymidine and determined the amount of radioactivity incorporated into TCA-precipitable high 
molecular weight DNA. RPE cells treated with the PDCD4-specific siRNAs displayed significantly reduced DNA 
synthesis activity compared to cells treated with control siRNA (Fig. 1d). Thus, in comparison to the control cells 
the number of cells in S-phase was significantly reduced in cultures treated with PDCD4-specific siRNA. This is 
consistent with our cell cycle measurements where almost no S-phase cells were visible after PDCD4 knockdown 
(Fig. 1b).
Overall, these experiments suggested a slowed-down entry of cells into S-phase when PDCD4 levels are low. 
To demonstrate the effect of PDCD4 knockdown on the G1/S-transition more directly we silenced PDCD4 
expression and synchronized the cell population by an additional treatment for 24 hours with 0.5 mM mimosine 
to block DNA-replication31. This leads to a reversible arrest of most of the cells at the G1/S boundary. The cells 
were then released into S-phase by washing them with medium without mimosine, followed by an analysis of 
the cell cycle profile immediately after the release of the cell cycle block and after 10 and 20 hours (Fig. 1e and 
Supplementary Table S1). Most of the G1-arrested, control siRNA-treated cells had entered into S-phase within 
10 hours after removal of mimosine. At 20 hours there was a distinct G2-peak and an increased G1 peak, suggest-
ing that a fraction of the cells had progressed through mitosis to reach the subsequent G1-phase. In contrast, only 
a small fraction of the cells treated with either of the PDCD4-specific siRNAs had entered into S-phase even after 
20 hours, indicating that PDCD4 knockdown had strongly blocked the G1/S-transition.
Defective G1/S-checkpoint control overrides the requirement for PDCD4 to undergo G1/S-transition. 
The finding that PDCD4 is required for the G1/S-transition seems counterintuitive considering that PDCD4 expres-
sion is often decreased in tumor cells1,2. We therefore hypothesized that defective G1/S-checkpoint control, which is 
a hallmark of many tumor cells, might circumvent the requirement for PDCD4 to pass the G1/S-boundary. To test 
whether defective G1/S-checkpoint control can override the requirement for PDCD4 for cells to enter into S-phase we 
investigated the effect of PDCD4 knockdown in HEK293T cells. These cells express the adenoviral E1A protein and 
the SV40 large T antigen, both of which sequester the retinoblastoma protein and allow transcription factor E2F to be 
active independently of cyclin/Cdk-induced phosphorylation, thereby inactivating the G1/S-checkpoint32,33. Although 
PDCD4 expression was silenced effectively in these cells (Fig. 2a) the cell cycle distribution of an asynchronous culture 
of HEK293T cells is almost indistinguishable, as judged by the slightly reduced height of the G2-cell peak and the 
almost similar height of the plateau of S-phase cells between the G1 and G2 peaks when comparing the control and 
the Pdcd4-knockdown cell populations (Fig. 2b and Supplementary Table S1). Moreover, we observed no significant 
change in the incorporation of 3H-thymidine into DNA (Fig. 2c). Furthermore, we used mimosine to block HEK293T 
cells in the cell cycle. Because mimosine arrests cells at the G1/S-boundary as well as cells that have already entered 
S-phase, mimosine-treatment of HEK293T cells resulted in a peak of G1-cells with a pronounced shoulder towards a 
higher DNA-content. Importantly, the cell cycle profiles recorded at 9 and 20 hours after removal of mimosine showed 
that PDCD4-silenced HEK293T cells had entered into S-phase upon removal of the drug similar to the control cells 
(Fig. 2d and Supplementary Table S1). This indicates that PDCD4 knockdown does not affect the G1/S-transition in 
HEK293T cells.
Knockdown of PDCD4 activates the G1/S-checkpoint in RPE cells by increasing the expression 
of p21WAF1/CIP1. Taken together, our data support the concept that PDCD4 knockdown activates the G1/S 
cell cycle checkpoint in RPE cells, thereby delaying cell cycle progression at the G1/S boundary. We have previ-
ously reported that knockdown of PDCD4 increases the activity and expression of p53 and thereby stimulates 
the expression of the p53 target gene CDKN1A26,28. CDKN1A encodes the Cdk-inhibitor p21WAF1/CIP1 that plays 
a key role at the G1/S-checkpoint. DNA damage induces p21WAF1/CIP1 expression via p53, which then inhibits 
Cdk activity and causes a G1/S cell cycle arrest34,35. Therefore, we hypothesized that the requirement for PDCD4 
to enter the S-phase was due to its ability to balance or counteract the basal activity of p53 in unstressed cells. 
This would suggest that decreasing the activity of p53 by an inhibitor would relieve the requirement for PDCD4 
expression for S-phase entry. To test this possibility, we employed pifithrin-α (PFT-α), an inhibitor that sup-
presses the p53-dependent activation of p53 target genes36. We knocked down PDCD4 both in the presence or 
absence of PFT-α and analyzed the expression of p21WAF1/CIP1 by western blot. Interestingly, we found a strong 
increase of p21WAF1/CIP1 expression following knockdown of PDCD4 in the absence of PFT-α (Fig. 3a), consistent 
with our earlier studies26 and demonstrating that silencing of PDCD4 increases p21WAF1/CIP1 expression also in 
RPE cells. As expected, in the presence of 30 μM PFT-α the increase of p21WAF1/CIP1 expression was strongly sup-
pressed. To measure S-phase entry of the cells we performed 3H-thymidine-labeling experiments. This showed 
that knockdown of PDCD4 in the absence of PFT-α strongly reduced DNA-synthesis activity (Fig. 3b), whereas 
the inhibition of DNA-synthesis activity by PDCD4 knockdown was less strong in the presence of PFT-α. It is 
possible that the DNA synthesis activity of PDCD4 knockdown cells did not reach the level of control cells in the 
presence of PFT-α because there was still a residual increase of p21WAF1/CIP1 in the presence of PFT-α. This could 
be due to a limiting concentration of the inhibitor, or could reflect a minor contribution of a p53-independent 
mechanism of stimulation of p21WAF1/CIP1 expression by PDCD4 silencing, as proposed recently37. Overall, our 
data show that the G1/S-cell cycle block induced by PDCD4 knock-down is caused, at least to a significant part, 
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by the p53-dependent increase of p21WAF1/CIP1 expression. PDCD4, therefore, plays a crucial role in counteracting 
basal p53 activity in unstressed cells.
Previously, we had observed that DNA damage down-regulates PDCD4 expression in HepG2 cells, suggesting 
a role of PDCD4 in the DNA-damage response28. This prompted us to examine whether the expression of PDCD4 
is also decreased in response to DNA damage in RPE cells. We employed UV-irradiation and the topoisomerase 
inhibitor mitoxantrone to induce DNA-damage, which we monitored by the DNA double strand break marker 
γ-H2AX38. The increase of g-H2AX staining between untreated cells (first lanes in panels C and D) and cells 
UV-irradiated or incubated with mitoxantrone confirmed that both treatments caused DNA damage, which was 
accompanied by virtually complete loss of PDCD4 expression (Fig. 3c,d). This suggested that PDCD4 does not 
act as an antagonist of p53 in the presence of genotoxic stress.
Silencing of PDCD4 in RPE cells affects the abundance and translation of multiple mRNAs. To 
obtain an integrated view of the functions of PDCD4, we employed RNA-Seq and ribosome profiling. This 
allowed us to explore the effect of PDCD4 knockdown in RPE cells on transcriptome-wide mRNA abundance 
and translation (Supplementary Fig. 1a). First, we used PDCD4 siRNA-2 and control siRNA in RPE cells 
(Supplementary Fig. 1b) and subjected them to RNA-Seq. We found that 496 genes were significantly upregulated 
and 750 genes were down-regulated by PDCD4 silencing. The heat map (Fig. 4a) shows all genes that are up- or 
down-regulated two-fold or more. We validated these changes by quantitative real-time PCR to confirm the 
expression of representative up- and down-regulated mRNAs (Fig. 4b).
To investigate whether PDCD4-dependent changes of mRNA expression affect specific biological processes 
we performed gene set enrichment analysis (GSEA39). mRNAs suppressed by PDCD4 silencing were strongly 
enriched in genes that are implicated in DNA replication, E2F targets and cell cycle regulation (Fig. 5a and 
Supplementary Table S2), substantiating our previous findings. Genes bound by the DREAM complex, a tran-
scriptional regulatory complex playing a key role in cell cycle regulation40–42, and genes with a peak of expres-
sion at the G1/S-checkpoint were strongly downregulated upon PDCD4 silencing. Further gene ontology (GO) 
term analysis of genes repressed by PDCD4 knockdown confirmed that these genes were involved in various 
DNA-related processes and aspects of cell cycle regulation. Genes that were up-regulated by PDCD4 knockdown 
were enriched in processes related to immune responses, aspects of extracellular matrix organization, cytokine 
signalling and motility (Fig. 5b). Overall, these findings suggest that decreased expression of PDCD4, as seen in 
many tumor cells, similarly affects a plethora of cellular processes. Furthermore, the data underline the notion 
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Figure 2. The G1/S-transition is independent of PDCD4 expression in HEK293T cells. (a) Silencing of Pdcd4 
expression by treatment of HEK293T cells with PDCD4-siRNA-2. (b) Cell cycle distribution of HEK293T cells 
treated with control or Pdcd4-specific siRNA-2. G1 and G2/M peaks are marked. (c) HEK293T cells treated 
for 72 hours with control or PDCD4-specific siRNA as in A were incubated for 1 h in medium supplemented 
with 10 μCi/mL 3H-thymidine. The radioactivity incorporated into DNA was determined by TCA-precipitation 
and liquid scintillation counting. The bars indicate the percent DNA synthesis (with standard deviation) of 
the PDCD4 siRNA treated cells relative to control cells. (d) HEK293T cells treated for 24 hours with control or 
PDCD4-specific siRNA were analysed for the G1/S-transition as in Fig. 1e. Positions of the G1 and G2 peaks are 
marked.
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that PDCD4 plays a crucial role in cell cycle regulation, particularly at the G1/S-phase transition and the subse-
quent S-phase.
To assess the global effects of PDCD4 on mRNA translation we performed ribosome profiling43,44 using RPE 
cells transfected with PDCD4-specific siRNA-2 or control siRNA. In this approach, polysomes of control and 
PDCD4 knockdown RPE cells are nuclease digested, ribosome-protected mRNA fragments (RPF) isolated and 
used for deep sequencing to generate “snapshots” of global translation. By combining these data with RNA-Seq 
data it is possible to determine the effect of PDCD4 silencing on the translation efficiency of individual mRNAs 
(Fig. 6a). By comparing the RNA-Seq and ribosome profiling data from control and PDCD4 knockdown cells 
we identified 496 transcripts that were significantly induced and 750 genes that were downregulated, while 1688 
genes remained unchanged by PDCD4 silencing (“RNA-Seq” in Fig. 6b). The RPF analysis showed that 592 
and 728 genes had increased or decreased RPF levels, while 4388 genes did not exhibit significant translational 
changes upon PDCD4 silencing (“RFP” in Fig. 6b). For the majority of transcripts the changes in translation levels 
correlate with altered mRNA abundance following PDCD4 silencing. mRNAs that are translationally regulated 
by PDCD4 knockdown (“translationally changed” in Fig. 6b) were defined as transcripts that exhibit altered RPF 
levels, while mRNA levels remained unaffected in response toPDCD4 silencing. This resulted in the identifica-
tion of 34 mRNAs (Supplementary Table S3). Since PDCD4 has been implicated in the translational suppression 
of mRNAs with structured 5′-UTRs3,4, we used mfold45 to examine the potential of the 5′-UTRs of the selected 
mRNAs to form secondary structures. We plotted the ΔG-values predicted for the folding of the 5’-UTRs sep-
arately for those mRNAs that showed increased or decreased translation after PDCD4 knockdown (Fig. 6c and 
µM PFT-α0     30      0     30
PDCD4
p21
β-actin
a
c d
0       10       20     30      60   s
PDCD4
β-actin
γ-H2AX
UV-irradiation
PDCD4
β-actin
γ-H2AX
0      0.3       1       3      µM
Mitoxantrone
b
50
100
3 H
-th
ym
id
in
e 
(%
)
***
***
0                  30      µM PFT-α
***
Figure 3. PDCD4 is linked to the G1/S checkpoint via the p53-p21WAF1/CIP1 axis. (a) Knockdown of PDCD4 
increases the expression of p21WAF1/CIP1. RPE cells were transfected with control siRNA or PDCD4-specific 
siRNA-2 in the absence or presence of 30 μM PFT-α. Total cell extracts were then analyzed by western blotting 
for expression of PDCD4, p21WAF1/CIP1 and β-actin. (b) RPE cells were labeled with 3H-thymidine for 1 hour, 
followed by TCA precipitation and liquid scintillation counting to determine their DNA synthesis activity. The 
bars indicate the percentage of DNA synthesis (with standard deviation) of the PDCD4 siRNA treated cells 
relative to control cells. Asterisks indicate statistical significance (***p < 0.001; students-t test). (c,d) DNA 
damage induced down-regulation of PDCD4 expression. RPE cells were exposed to UV light for the indicated 
times, using a germicidal UV-C lamp in a tissue culture hood or were cultivated in the presence of the indicated 
concentrations of mitoxantrone. Cells were incubated for 16 hours and total cell extracts were analyzed by 
western blotting for expression of PDCD4, the DNA double strand break marker γ-H2AX, and β-actin.
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Supplementary Table S3). This indicated that mRNAs whose translation was increased by PDCD4 silencing had 
more negative predicted ΔG-values, reflecting a higher secondary structure potential of their 5′-UTRs, than 
those mRNAs whose translation was decreased by the PDCD4 knockdown. We further identified 85 mRNAs that 
remained stable at the level of translation but were altered at the mRNA levels upon PDCD4 silencing and, hence, 
were also differentially translated between control and PDCD4 knockdown cells (Supplementary Table S3). 
We determined the predicted ΔG-values for folding of the 5′-UTRs of the selected mRNAs whose translation 
was increased or decreased by PDCD4 silencing (Fig. 6d and Supplementary Table S3). Similar to our previous 
analysis this showed that mRNAs whose translation was more effective after PDCD4 knockdown have lower 
ΔG-values for folding of their 5′-UTRs than mRNAs whose translation was decreased. Combining these differ-
ent sets of mRNAs, we identified 62 translationally up-regulated and 57 down-regulated mRNAs upon PDCD4 
silencing (“translationally changed” in Fig. 6b), of which mRNAs with increased translation after knockdown of 
PDCD4 possess more highly structured 5′-UTRs than mRNAs whose translation is decreased when PDCD4 is 
silenced. (Fig. 6e). Although we cannot exclude indirect effects of PDCD4 silencing on the translation of specific 
mRNAs, our analyses are consistent with the concept that PDCD4 suppresses the translation of mRNAs that con-
tain structured 5′-UTRs. Besides the identification of mRNAs that are potential targets of translational suppres-
sion by PDCD4, our work has also revealed mRNAs that show decreased translation upon PDCD4 knockdown. 
The identification of groups of mRNAs whose translation is either positively or negatively regulated by PDCD4 
sets the stage for future work to understand the role of PDCD4 in translation regulation in more detail.
Discussion
PDCD4 is a multifunctional protein initially described as a transformation suppressor in a murine keratino-
cyte transformation model11. Subsequent work has strongly suggested that PDCD4 acts as a tumor suppres-
sor in a broad spectrum of human tumor types1,2 and has shown that decreased expression of human PDCD4 
contributes to tumor development in various ways, for example by enhancing the motility and invasiveness of 
the tumor cells18–20,23–25. Most of the studies addressing the function of human PDCD4 have employed various 
tumor cells, raising the question whether these studies fully reflect the function of human PDCD4 in normal 
cells. Therefore, we have used a telomerase-immortalized human epithelial cell line to highlight novel aspects of 
PDCD4′s function.
Our work shows for the first time that PDCD4 is required for the G1/S-phase transition. We observed that 
siRNA-mediated down-regulation of PDCD4 expression strongly impaired the entry of the cells into S-phase, 
decreased DNA synthesis activity and reduced cell proliferation rate. Our results suggest that the role of PDCD4 
as a G1/S cell cycle regulator is linked to the activity of p53. More specifically, our work supports the notion 
that PDCD4 is required to counteract the activity of p53, preventing the activation of the G1/S-checkpoint in 
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Figure 4. Pdcd4 knockdown induces transcriptome-wide changes of mRNA expression. (a) Heat map of all 
mRNAs whose expression levels were significantly altered (padj value < 0.05) after silencing of PDCD4 by a 
log2-fold change > 0.5 or <−0.5. The individual columns represent the results of three independent samples 
from cells transfected with control siRNA (control) and two independent samples of cells transfected with 
PDCD4 siRNA-2 (si-2). Selected genes are marked on the right side. (b) Real-time PCR analysis of selected 
up- and down-regulated RNAs. The columns indicate mRNA abundance in control siRNA (black bars) and 
PDCD4 siRNA-2 (grey bars) treated RPE cells. Individual expression levels determined from three independent 
biological replicates are marked by white dots. Asterisks indicate statistical significance (*p < 0.05; **p < 0.01; 
***p < 0.001; students-t test).
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unstressed cells and permitting them to enter into S-phase. In this scenario, knockdown of PDCD4 leads to 
increased p53-dependent expression of p21WAF1/CIP1 and concomitant activation of the G1/S-checkpoint. Using 
HeLa cells, we have previously observed increased p21WAF1/CIP1 expression after knockdown of PDCD426. 
-3 -2 -1 0 1 2 3
DNA_REPLICATION
CELL_CYCLE_G1_S_PHASE_TRANSITION
SISTER_CHROMATID_SEGREGATION
MITOTIC_NUCLEAR_DIVISION
DNA_REPLICATION_INITIATION
ORGANELLE_FISSION
DNA_RECOMBINATION
CENTROMERE_COMPLEX_ASSEMBLY
CELL_DIVISION
DNA_SYNTHESIS_INVOLVED_IN_DNA_REPAIR
STRAND_DISPLACEMENT
DNA_GEOMETRIC_CHANGE
DNA_REPAIR
MEIOTIC_CELL_CYCLE_PROCESS
CELL_CYCLE_CHECKPOINT
MICROTUBULE_ORGANIZING_CENTER_ORGANIZATION
TELOMERE_ORGANIZATION
PROTEIN_LOCALIZATION_TO_CHROMOSOME
DNA_PACKAGING
CHROMATIN_REMODELING
NEG._REGULATION_OF_CELL_DIVISION
NUCLEOTIDE_EXCISION_REPAIR_DNA_GAP_FILLING
CELL_CYCLE_G2_M_PHASE_TRANSITION
PROTEIN_SUMOYLATION
REGULATION_OF_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR
TRNA_TRANSPORT
REGULATION_OF_UBIQUITIN_PROTEIN_LIGASE_ACTIVITY
RESPONSE_TO_TYPE_I_INTERFERON
NAD_METABOLIC_PROCESS
REGULATION_OF_SYNAPSE_ASSEMBLY
INFLAMMATORY_RESPONSE
MULTICELLULAR_ORGANISM_METABOLIC_PROCESS
REGULATION_OF_RELEASE_OF_CYTOCHROME_C_FROM_MITOCHONDRIA
EXTRACELLULAR_MATRIX_DISASSEMBLY
NUCLEOTIDE_PHOSPHORYLATION
HOMOPHILIC_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES
NEG._REGULATION_OF_LYMPHOCYTE_MEDIATED_IMMUNITY
ATP_GENERATION_FROM_ADP
EXTRACELLULAR_STRUCTURE_ORGANIZATION
MULTICELLULAR_ORGANISMAL_MACROMOLECULE_METABOLIC_PROCESS
n = 181
n = 98
n = 147
n = 315
n = 27
n = 392
n = 170
n = 37
n = 390
n = 66
n = 26
n = 75
n = 387
n = 99
n = 168
n = 74
n = 84
n = 34
n = 135
n = 117
n = 48
n = 23
n = 123
n = 104
n = 144
n = 30
n = 15
n = 39
n = 37
n = 40
n = 230
n = 55
n = 34
n = 48
n = 40
n = 67
n = 16
n = 25
n = 202
n = 48
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****
*****
****
****
****
***
***
***
***
***
**
**
**
*
*
*
*
*
*
*
*
*
**
**
**
**
**
**
**
normalized enrichment score
ES -0.71
NES -2.71
FDR 0.0
ES -0.67
NES -2.92
FDR 0.0
ES -0.65
NES -2.49
FDR 0.0
ES -0.72
NES -2.77
FDR 0.0
E
nr
ic
hm
en
ts
co
re
 (E
S
)
E
nr
ic
hm
en
ts
co
re
 (E
S
)
E
nr
ic
hm
en
ts
co
re
 (E
S
)
E
nr
ic
hm
en
ts
co
re
 (E
S)
DNA_REPLICATION
FISCHER_G1_S_CELL_CYCLE
E2F_TARGETS
FISCHER_DREAM_TARGETS
a
b
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charts revealing the role of PDCD4 in cell cycle regulation. (b) GO-term (biological process) enrichment 
analysis of genes up- and downregulated by PDCD4 silencing. Significantly differentially expressed gene sets 
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However, unlike the work reported here, knockdown of PDCD4 in HeLa cells only showed aberrant cell behav-
iour in the presence of DNA damage but did not result in overt cell cycle defects. This might be due to the defec-
tive nature of the G1/S-checkpoint in these cells caused by the sequestration of the RB protein by the human 
papilloma virus E7 protein expressed in HeLa cells46. HEK293T cells also have a defective G1/S checkpoint 
(resulting from the expression of the adenovirus E1A and E1B proteins). We found that the requirement for 
PDCD4 expression for S-phase transition is indeed absent in these cells. Overall, our work identifies a novel 
role of PDCD4 as a cell cycle regulator that balances p53 activity in unstressed cells, presumably to prevent 
G1/S-checkpoint activation. Interestingly, we also showed before28 and confirmed here that induction of DNA 
damage leads to down-regulation of PDCD4 expression, which suggests that this function of PDCD4 is abolished 
under conditions of genotoxic stress.
The identification of a pro-proliferative role for PDCD4 in the cell cycle is somewhat unexpected in the light 
of its function as a tumor suppressor. At first glance, low expression of PDCD4 in tumor cells would be expected 
to impede the cell cycle, however, many tumor cells have a defective G1/S checkpoint as a result of p53 or other 
mutations, neutralizing the inhibitory effects of low PDCD4 expression on the G1/S-transition. Transcription 
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profiling has revealed a large number of genes that are up- or down-regulated upon PDCD4 knockdown, pro-
viding an unbiased view of the cellular processes that are affected by PDCD4. Consistent with previous stud-
ies showing increased motility and invasiveness18–20,23–25, GO-term analysis for the biological function of the 
genes up-regulated by PDCD4 knockdown identifies functions related to extracellular matrix organization and 
cell adhesion amongst others. GO-term analysis of genes down-regulated by PDCD4 knockdown identifies a 
plethora of cell cycle- and DNA-related functions that are inhibited when PDCD4 expression is low, such as 
DNA-replication, DNA-recombination, DNA-repair, telomere organization, chromosome segregation and chro-
matin remodelling, amongst others. This suggests that decreased PDCD4 expression contributes to tumor devel-
opment and progression by compromising genomic integrity.
Finally, our ribosome profiling analysis shows that the translation of the majority of transcripts was not 
affected by silencing of PDCD4 because changes in the abundance of ribosome footprints correlated with changes 
in the expression levels of these mRNAs. By focussing on transcripts that were affected in only one parameter (i.e. 
mRNA expression level or the frequency of RPF reads) in response to PDCD4 knockdown, we have identified 
several mRNAs whose translation was moderately increased following PDCD4 knockdown, suggesting that they 
might be translational targets of PDCD4. These RNAs exhibit an increased potential to form stable secondary 
structures in their 5′-UTRs compared to mRNAs showing decreased translation after PDCD4 silencing, consist-
ent with the notion that Pdcd4 preferentially inhibits translation of RNAs with structured 5′-UTRs3,4. Similarly, 
PDCD4 knockdown stimulates the translation of RNAs that lack secondary structure in their 5′-UTR or that 
have short 5′-UTRs. Whether the translation of these RNAs is suppressed by binding of PDCD4 to their cod-
ing regions, as already reported for certain mRNAs29,30,47, or whether PDCD4 affects their translation indirectly 
remains to be addressed by future studies. In addition to the identification of potential target mRNAs for transla-
tional repression by PDCD4 we have also discovered mRNAs whose translation is positively affected by PDCD4. 
Whether PDCD4 mediates these effects directly or indirectly and whether this reflects a novel aspect of the func-
tion of PDCD4 in translation, remains to be investigated in future work. Overall, our study is the first analysis 
of genome-wide changes of mRNA abundance and translation induced by PDCD4 silencing in an immortalized 
human epithelial cell line. This sets the stage for more detailed studies on the role of PDCD4 in the future.
Materials and Methods
Cells and siRNA transfections. hTERT-RPE-1 is a line of telomerase-immortalized human retina pigment 
epithelial cells48. The cells were grown in DMEM/Ham’s F12 medium supplemented with 10% fetal calf serum. 
PDCD4 expression was silenced with siRNA duplexes targeting the sequences CACCAAUCAUACAGGAAUA 
(PDCD4 siRNA-1) or GCUUCUUUCUGACCUUUGU (PDCD4 siRNA-2). SiRNA targeting Renilla luciferase 
(AAACAUGCAGAAAAUGCUG) was used as negative control. siRNAs (100 nM) were reversely transfected 
using Lipofectamine® RNAiMax (ThermoScientific), according to manufacturer’s protocols. Cells were harvested 
48 to 72 h after transfection.
Cell cycle analysis. Cells were trypsinized, fixed with 70% ice-cold ethanol in PBS for 1 h or longer at 
−20 °C, washed with PBS (+0.5% BSA) and stained with propidium iodide (50 μg/mL PI and 25 μg/mL RNase 
A in PBS) for 1 h at room temperature. In some experiments, cells were synchronized by incubation for 24 h in 
growth medium containing 0.5 mM mimosine. To release the cells into the cell cycle they were washed twice with 
grown medium lacking mimosine. Flow cytometry analysis was performed using a Beckman-Coulter Cytomics 
FC500 flow cytometer. 10 000 to 15 000 cells were counted per condition in every experiment.
Antibodies. Western blotting of PDCD4 was performed using a rabbit anti PDCD4 antiserum raised against 
the N-terminus of human Pdcd426. Antibodies against p21WAF1/CIP1 (05–345, Millipore), γ-H2AX (GTX61796, 
Genetex) and β-actin (AC15, Sigma-Aldrich) were obtained from commercial sources.
Quantitative real-time PCR. Total cellular RNA was isolated with TRIzolTM Reagent (Invitrogen), as recom-
mended by the manufacturer. Total RNA (2 μg) was reverse transcribed with the First Strand cDNA Synthesis Kit 
(K1612, ThermoScientific) using OligoT primers in 20 μL according to the manufacturer’s instructions. Real-time 
RT-PCR reactions were carried out in 96-well plates using Power SYBR Green PCR Master Mix (Applied 
Biosystems). Reactions were performed using a StepOnePlus RT-PCR instrument (Applied Biosystems) and the 
following parameters: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s. Each experiment 
included a no-template control. PCR reaction specificity was confirmed by melting curve analysis of the products. 
Primer sequences are given in Supplementary Table S4. Relative gene expression was calculated by the ΔΔCT 
method:49 First, ΔCT values were calculated by subtracting the CT-values obtained for individual mRNAs from 
those obtained for β-actin mRNA. Then, ΔΔCT values were calculated by subtracting the ΔCT values of Pdcd4 
siRNA-treated cells from those of control siRNA-treated cells. All experiments were conducted with at least three 
biological replicates.
3H-thymidine labeling. Cells were incubated with growth medium supplemented with 10 μCi/ml 
3H-thymidine for 1 h. The cells were then washed with PBS, lysed in PBS containing 1% SDS and heated to 
95 °C to reduce the viscosity. Aliquots were then spotted on Whatman filter paper and washed 2 times for 15 min 
with 10% trichloracetic acid (TCA) and once with ethanol. The filter paper was dried and the radioactivity was 
determined in a scintillation counter. To correct for differences in the cell number between Pdcd4-specific and 
control knockdown samples aliquots of the lysed cells were spotted on nitrocellulose membrane and hybridized 
to a 32P-labeled probe of total human DNA. Alternatively, aliquots of the lysed cells were analyzed by SDS-PAGE 
and western blotting for expression of β-actin to determine the relative number of cells.
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RNA-seq. For RNA-seq of poly(A)-selected RNA, RPE cells were incubated for 24 h after transfection with 
siRNA (Pdcd4 siRNA-2 or control siRNA), and cells were directly lysed in TRIzolTM reagent (Invitrogen). Total 
RNA was extracted with 1-bromo-3-chloropropane, precipitated with EtOH, resuspended in milliQ water and 
treated with TURBO DNase (Ambion) for 30 min at 37 °C, 1400 rpm. RNA was extracted again with acidic phe-
nol to remove DNase. The quality of the RNA was examined with an Agilent Bioanalyzer. Sequencing libraries of 
poly(A)-enriched RNA were finally generated with the TruSeq Stranded mRNA LT Kit (Illumina).
Ribosome profiling. Ribosome profiling was carried out as previously described44. RPE cells were incu-
bated for 24 h after transfection with siRNA (PDCD4 siRNA-2 or control siRNA). 2 h before harvesting the cul-
ture medium was replaced with fresh medium. To stabilize elongating ribosomes, cells were treated with 100 µg/
mL cycloheximide (CHX) for 5 min at 37 °C, following a washing step with ice cold PBS (containing 100 µg/mL 
CHX). Cells were then lysed in lysis buffer (10 mM Tris-HCl (pH 7.4), 10 mM MgCl2, 100 mM NaCl, 1% Triton, 
1 mM DTT, 100 µg/mL CHX) per sample. Each sample consisted of cells from 8 tissue culture dishes (10 cm 
diameter), and cell debris was pelleted at 4 °C, 10 000 x g for 3 min. 10 OD260 units of cell extract were then sup-
plemented with 900 U RNase I (Ambion) and 0.5% deoxycholate and treated for 20 min at 22 °C and 800 rpm in 
a thermomixer. The reaction was stopped by addition of 240 U SUPERase In (Ambion)( + 0.5% deoxycholate) 
and extracts were fractionated by centrifugation at 4 °C, 35 000 rpm for 3 h in a SW-41 Ti swinging-bucket rotor 
(Beckman Coulter) on 10–50% sucrose density gradients (20 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 100 mM 
NH4Cl, 2 mM DTT, 100 µg/mL CHX). Gradients were fractionated at 0.75 mL/min with continuous monitoring 
of the OD254 using a Biocomp Instruments Gradient Station (Teledyne Isco). Monosome fractions were collected 
and, following addition of 1% SDS, flash-frozen and stored at −80 °C. RNA was isolated from gradient fractions 
by the hot acid phenol method (1-bromo-3-chloropropane used instead of chloroform), and ribosome footprints 
were purified from monosome RNA by size selection of 28–30 nt fragments (excluding a major band around 31 
nt) on 15% polyacrylamide, 8 M urea, 1xTBE gels. Sequencing libraries from ribosome-protected footprints were 
generated by 3′-end dephosphorylation, followed by 3′-adapter ligation, reverse transcription, and circularization 
as described in44.
Sequencing data analysis. The analysis of the ribosome profiling and RNA-seq datasets was essentially 
performed as described in44. Briefly, libraries for ribosome profiling and RNA-Seq were sequenced on an Illumina 
NextSeq sequencer. Ribosome-profiling reads were processed by clipping adapter sequences and trimming of 
the 4 randomized nucleotides in the linker with the FASTX-Toolkit version 0.0.13 (http://hannonlab.cshl.edu/
fastx_toolkit). After processing, residual rRNA sequences were remove from ribosome-profiling datasets using 
bowtie version 1.0.0.50. Ribosome-profiling and raw RNA-Seq reads were mapped to hg38 transcripts (UCSC 
canonical transcripts extended 18 bp into the UTRs). Count tables of mapped reads were generated using cus-
tom scripts and differential expression determined with DESeq. 251. Differential expression was scored using an 
adjusted p-value of 0.05 for the hypothesis of a changed gene (res) and unchanged expression was additionally 
scored using an adjusted p-value of 0.1 for the hypothesis of an unchanged gene (resLA). Transcripts translation-
ally changed were defined with an adjusted p-value for mRNA or ribosome profiling data >0.05 (res) with the 
corresponding adjusted p-value in the other category (resLA) < 0.1.
Gene set enrichment analysis (GSEA). GSEA was carried out using the GSEA preranked tool (http://
software.broadinstitute.org/gsea/index.jsp) with 1,000 gene set permutations. The genes in the expression dataset 
were ranked by their log2 fold change. Redundant terms were removed with REVIGO52.
Calculation of ΔG values for 5′-UTR secondary structure formation. The 5′UTR sequences of the 
relevant mRNAs were retrieved from the NCBI nucleotide sequence data base and truncated immediately after 
the start codon. If several mRNA sequences were available sequence variant 1 was chosen. The sequences were 
then submitted to the RNAfold web server (http://rna.tbi.univie.ac.at) to predict the mimimum free energy of the 
optimal secondary structure (Supplementary Table S5).
Data access. The RNA-seq and ribosome profiling data from hTERT-RPE-1 cells (PDCD4 siRNA2 and con-
trol siRNA) have been submitted to the NCBI Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo/) 
under accession number GSE138533 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138533).
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